I've provided you facts about those 3 IP being more advanced than just Ph1/b clinical trial to near development stages which will attract T/O from BP, if you are clueless about what I said and their market potential then that's your problem. HER-Vaxx's market was limited to just advanced gastric cancer to be used with chemotherapy, I still think there's value as there a potential the IP can be advanced to use as a combination with chemotherapy for other cancer treatment and not all alternate treatment will work on patient so chemotherapy will be their last option but BP seem to pivot to alternate treatment investment and not chemotherapy????
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)